Molecular signatures of epithelial ovarian cancer: Analysis of associations with tumor characteristics and epidemiologic risk factors

Cancer Epidemiology Biomarkers and Prevention

Volumn 22, Issue 10, 2013, Pages 1709-1721

  Schildkraut, Joellen M ^a,d   Iversen, Edwin S ^b,d   Akushevich, Lucy ^d   Whitaker, Regina ^c   Bentley, Rex C ^b   Berchuck, Andrew ^a,c,d   Marks, Jeffrey R ^b  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b Department of Statistical Science ^*  (United States)

^c Division of Pediatric Oncology   (United States)

^d DUKE CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ORAL CONTRACEPTIVE AGENT;

ADOLESCENT; ADULT; ADVANCED CANCER; AGED; ARTICLE; BREAST; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER GRADING; CANCER LOCALIZATION; CANCER PROGNOSIS; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CASE CONTROL STUDY; CELL DIVISION; FAMILY HISTORY; FEMALE; FIRST DEGREE RELATIVE; GENE EXPRESSION; HUMAN; IMMUNOREACTIVITY; INFLAMMATION; MAJOR CLINICAL STUDY; MENARCHE; MICROARRAY ANALYSIS; OVARY CANCER; OVARY CARCINOMA; PERITONEUM CANCER; PRIORITY JOURNAL; RISK FACTOR;

ADULT; AGED; FEMALE; GENE EXPRESSION; HUMANS; MIDDLE AGED; NEOPLASMS, GLANDULAR AND EPITHELIAL; NORTH CAROLINA; OVARIAN NEOPLASMS; RISK FACTORS; YOUNG ADULT;

EID: 84886420667     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-13-0192     Document Type: Article

References (11)

1. Pearce CL, Templeman C, Rossing MA, Lee A, Near AM, Webb PM, et al. Association between endometriosis and risk of histological subtypes of ovarian cancer: a pooled analysis of case-control studies. Lancet Oncol 2012;13:385-94.
2. Marchbanks PA, Wilson H, Bastos E, Cramer DW, Schildkraut JM, Peterson HB. Cigarette smoking and epithelial ovarian cancer by histologic type. Obstet Gynecol 2000;95:255-60.
3. Tothill RW, Tinker AV, George J, Brown R, Fox SB, Lade S, et al. Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. Clin Cancer Res 2008;14: 5198-208.
4. Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature 2011;474:609-15.
5. Schildkraut JM, Iversen ES, Wilson MA, Clyde MA, Moorman PG, Palmieri RT, et al. Association between DNA damage response and repair genes and risk of invasive serous ovarian cancer. PLoS ONE 2010;5:e10061.
6. Moorman PG, Calingaert B, Palmieri RT, Iversen ES, Bentley RC, Halabi S, et al. Hormonal risk factors for ovarian cancer in premenopausal and postmenopausal women. Am J Epidemiol 2008;167: 1059-69.
7. Sfakianos GP, Iversen ES, Whitaker R, Akushevich L, Schildkraut JM, Murphy SK, et al. Validation of ovarian cancer gene expression signatures for survival and subtype in formalin fixed paraffin embedded tissues. Gynecol Oncol 2013;129:159-64.
8. Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, Scherf U, et al. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 2003;4: 249-64.
9. Smyth GK, Michaud J, Scott HS. Use of within-array replicate spots for assessing differential expression in microarray experiments. Bioinformatics 2005;21:2067-75.
10. Verhaak RG, Tamayo P, Yang JY, Hubbard D, Zhang H, Creighton CJ, et al. Prognostically relevant gene signatures of high-grade serous ovarian carcinoma. J Clin Invest 2013;123:517-25.
11. du Bois A, Reuss A, Pujade-Lauraine E, Harter P, Ray-Coquard I, Pfisterer J. Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d'Investigateurs Nationaux Pour les Etudes des Cancers de l'Ovaire (GINECO). Cancer 2009;115:1234-44.